Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors (Q40381044)

From Wikidata

Jump to navigation Jump to search

scientific article published on 10 August 2005

Language	Label	Description	Also known as
English	Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors	scientific article published on 10 August 2005

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

author name string

Gustavo Helguera

1

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Gustavo Helguera

2

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Jay S Dela Cruz

3

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Christine Lowe

4

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Patrick P Ng

5

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Ryan Trinh

6

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Sherie L Morrison

7

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Manuel L Penichet

8

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

language of work or name

0 references

publication date

10 August 2005

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

304-316

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

The ErbB/HER receptor protein-tyrosine kinases and cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Oncogenic kinase signalling

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Humanization of an anti-p185HER2 antibody for human cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

First-line Herceptin monotherapy in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

The IL-2 mediated amplification of cellular cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Characterization of lymphokine-activated killing by human peripheral blood mononuclear cells stimulated with interleukin 2 (IL-2) analogs specific for the intermediate affinity IL-2 receptor

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Natural killer (NK) cell stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Anti-tumor activity of interleukin-2-producing tumor cells and recombinant interleukin 12 against mouse glioma cells located in the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Strategies for designing and optimizing new generation vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Enhanced adjuvant effect of granulocyte-macrophage colony-stimulating factor plus interleukin-12 compared with either alone in vaccine-induced tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Combined IL-12 and GM-CSF gene therapy for murine hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Production and properties of chimeric antibody molecules

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

An IgG3-IL2 fusion protein activates complement, binds Fc gamma RI, generates LAK activity and shows enhanced binding to the high affinity IL-2R.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Amino acid sequence and post-translational modification of human interleukin 2

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Human/mouse chimeric monoclonal antibodies with human IgG1, IgG2, IgG3 and IgG4 constant domains: electron microscopic and hydrodynamic characterization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

Granulocyte-macrophage colony-stimulating factor: pleiotropic cytokine with potential clinical usefulness

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.073

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2005.07.073

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40381044&oldid=1896485087"